Known hypersensitivity to any of the ingredients of Reyataz, including atazanavir. Reyataz is contraindicated when co-administered with drugs that are highly dependent on CYP3A4 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Severe hepatic insufficiency.
Alpha 1-adrenoreceptor Antagonist: Alfuzosin: Potential for increased alfuzosin concentrations which can result in hypotension.
Antiarrhythmics: Quinidine: Contraindicated if Reyataz is co-administered with ritonavir due to potential for serious and/or life-threatening reactions eg, cardiac arrhythmias.
Calcium-Channel Blockers: Bepridil: Potential for serious and/or life-threatening adverse events. Contraindicated if Reyataz is co-administered with ritonavir.
Ergot Derivatives: Dihydroergotamine, Ergotamine, Ergonovine, Methylergonovine: Potential for serious and/or life-threatening events eg, acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
GI Motility Agent: Cisapride: Potential for serious and/or life-threatening reactions eg, cardiac arrhythmias.
HMG-CoA Reductase Inhibitors: Lovastatin, Simvastatin: There may be potential for serious reactions eg, myopathy including rhabdomyolysis. (See HMG-CoA Reductase Inhibitors: Atorvastatin, Cerivastatin as follows.)
Herbal Products: St. John's Wort (Hypericum perforatum): Patients taking Reyataz should not use products containing St. John's wort because co-administration may be expected to reduce plasma concentrations of atazanavir. This may result in loss of therapeutic effect and development of resistance.
Neuroleptic: Pimozide: Potential for serious and/or life-threatening reactions eg, cardiac arrhythmias.
Sedative Hypnotics: Orally-Administered Midazolam, Triazolam: Potential for increased concentrations of the sedative hypnotic and increased risk of prolonged sedation or respiratory depression.
PDE5 Inhibitor: Sildenafil when used for the treatment of pulmonary arterial hypertension: A safe and effective dose in combination with Reyataz has not been established for sildenafil when used for the treatment of pulmonary hypertension. There is increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, priapism and syncope).